Products

Daclahep Tablet: The Potent NS5A Inhibitor for Hepatitis C Cure – Global Supply by Ernest Oncology The evolution of Direct-Acting Antivirals (DAAs) has made Hepatitis C (HCV) a highly curable condition. Daclahep, containing Daclatasvir (60mg), is a cornerstone of modern HCV therapy. When used in combination with other antivirals like Sofosbuvir, it provides a robust, all-oral treatment pathway that targets the virus across multiple genotypes, ensuring high Sustained Virologic Response (SVR) rates. Ernest Oncology, the premier pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We specialize in the secure, GMP-certified international distribution of Daclahep to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa. What is Daclahep? Daclahep is a high-quality generic version of the breakthrough medication Daklinza. As a powerful NS5A inhibitor, it prevents the Hepatitis C virus from replicating and assembling new viral particles. Because it is rarely used alone, it is most commonly paired with Sofosbuvir to create a pan-genotypic treatment regimen that eliminates the need for interferon injections. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 3, & 4): Particularly effective when combined with Sofosbuvir for these prevalent genotypes. Advanced Liver Disease: A vital component for patients with compensated or decompensated cirrhosis. Post-Liver Transplant: Used in specialized regimens to prevent HCV recurrence after transplantation. HCV/HIV Co-infection: Highly recommended for patients managing both infections due to its favorable drug-interaction profile. Detailed Product Information: Daclahep (60mg) Feature, Technical Specification Active Ingredient: Daclatasvir (60mg) Drug Class: NS5A Replication Complex Inhibitor Manufacturer: Hetero Healthcare / Natco Pharma (India) Form film-coated tablets (28 Tablets per pack) Standard Regimen, 12 to 24 Weeks (based on clinical profile) Quality Standard, GMP Certified Manufacturing Mechanism of Action: Disrupting Viral Assembly Daclahep works by targeting a specific protein within the Hepatitis C virus: NS5A Protein Inhibition: Daclatasvir binds to the NS5A non-structural protein. This protein is essential for both the replication of the viral RNA and the assembly of the new virus particles (virions). Viral Clearance: By blocking this protein, the medication stops the virus from spreading to new liver cells, allowing the body’s immune system and companion antivirals to clear the infection. Dosage and Administration Standard Dose: One 60mg tablet taken orally, once daily. Combination Therapy: Must be taken with Sofosbuvir (400mg) or as directed by a hepatologist. Administration: Can be taken with or without food. Consistency is vital—doses should be taken at the same time every day. Storage: Store in a cool, dry place below 30°C, protected from light and moisture. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the complex logistics of international pharmaceutical trade. We ensure that Daclahep—manufactured by India's leading pharmaceutical giants—is delivered through verified, temperature-controlled, and legal channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ access programs in London and nationwide. United States: Providing cost-effective supply for clinical research and specialized pharmacy networks. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s premier medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health initiatives and regional distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of oncology and antiviral medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Hepcinat Plus Tablet: The Advanced Dual-Action Cure for Hepatitis C – Global Supply by Ernest Oncology The introduction of Direct-Acting Antiviral (DAA) combinations has revolutionized the treatment of Chronic Hepatitis C, turning a once-chronic condition into a curable one. Hepcinat Plus, a potent fixed-dose combination of Sofosbuvir (400mg) and Daclatasvir (60mg), stands at the forefront of this medical breakthrough. This combination is highly effective across multiple genotypes and is widely prescribed for its high cure rates and manageable side-effect profile. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Hepcinat Plus to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Hepcinat Plus? Hepcinat Plus is a high-quality generic version of the combination therapy used to treat Chronic Hepatitis C. By combining two distinct antiviral mechanisms, Hepcinat Plus eliminates the need for interferon injections, which were previously the standard of care but carried significant side effects. Clinical data indicates a Sustained Virologic Response (SVR12)—the clinical definition of a cure—in over 95% of treated patients. Primary Indications & Medical Uses Chronic Hepatitis C (Multiple Genotypes): Specifically effective for Genotypes 1, 3, and 4, providing a robust treatment path for a wide range of patients. HCV/HIV Co-infection: Safe for use in patients managing both Hepatitis C and HIV-1, with a well-documented drug-interaction profile. Patients with Cirrhosis: Effective for patients with compensated liver disease, often used to prevent further liver damage and the need for transplantation. Detailed Product Information: Hepcinat Plus (400mg/60mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Daclatasvir (60mg) Drug Class: NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturer: Natco Pharma (India) Form: Film-coated tablets (28 Tablets per bottle) Treatment Duration, Standard 12-Week Course Success Rate: >95% Sustained Virologic Response (SVR) Quality Standard, GMP Certified Production Mechanism of Action: The Dual-Inhibitor Strategy Hepcinat Plus works by attacking the Hepatitis C virus at two critical stages of its replication cycle: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It acts as a “chain terminator,“ preventing the virus from copying its genetic material (RNA). Daclatasvir (60mg): An NS5A inhibitor. It blocks the NS5A protein, which the virus requires for both the replication of the virus and the assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken orally, once daily. Administration: Can be taken with or without food. Consistency is critical; the dose should be taken at the same time every day to maintain optimal antiviral levels in the blood. Storage: Store in the original moisture-proof packaging at room temperature (below 30°C) away from direct sunlight. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Hepcinat Plus—manufactured by Natco Pharma—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology clinics and “Named Patient“ programs in London and across the UK. United States: Providing affordable access for specialized pharmacy requirements and clinical research. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s leading medical hubs and specialty pharmacies. Australia & South Africa: Reliable bulk supply for public health initiatives and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Myhepdvir Tablet: The Definitive Treatment for Chronic Hepatitis B – Global Supply by Ernest Oncology The management of Chronic Hepatitis B (HBV) requires high-potency antiviral therapy to prevent liver complications such as cirrhosis and hepatocellular carcinoma. Myhepdvir, containing Tenofovir Alafenamide (25mg), represents the latest advancement in Nucleotide Reverse Transcriptase Inhibitor (NtRTI) therapy. Designed for superior efficacy with a safer profile for bone and kidney health, Myhepdvir is a cornerstone in modern HBV treatment protocols. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Myhepdvir to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Myhepdvir? (The TAF Advantage) Myhepdvir is a premium generic version of Vemlidy. It utilizes Tenofovir Alafenamide (TAF), a prodrug of Tenofovir. Compared to the older Tenofovir Disoproxil Fumarate (TDF), TAF is more stable in the plasma and delivers the active metabolite more efficiently to the liver cells (hepatocytes). This efficiency allows for a significantly lower dose (25mg vs 300mg), which results in 90% less Tenofovir in the bloodstream, drastically reducing the risk of renal toxicity and bone mineral density loss. Primary Indications & Medical Uses Chronic Hepatitis B Virus (HBV): For the treatment of chronic HBV infection in adults with compensated liver disease. HBeAg-Positive & HBeAg-Negative Patients: Effective across various viral profiles and stages of chronic infection. Long-term Suppression: Designed for long-term use to keep viral loads at undetectable levels and promote ALT (liver enzyme) normalization. Detailed Product Information: Myhepdvir (25mg) Feature, Technical Specification Active Ingredient: Tenofovir Alafenamide (25mg) Therapeutic Class: Nucleotide Reverse Transcriptase Inhibitor (NtRTI) Manufacturers: Mylan (Viatris) / Natco Pharma (India) Form: Film-coated tablets (30 Tablets per bottle) Treatment Type: Long-term antiviral suppression Safety Profile: Superior Renal & Bone Safety (compared to TDF) Quality Standard, GMP Certified Production Mechanism of Action: Target-Specific Inhibition Myhepdvir works by inhibiting the Hepatitis B virus polymerase, an enzyme required for the virus to replicate its DNA. Intracellular Activation: Once ingested, Myhepdvir is converted into Tenofovir diphosphate inside the liver cells. Chain Termination: Tenofovir diphosphate competes with the natural substrate of the viral DNA, incorporating itself into the viral DNA chain and causing immediate termination of replication. Dosage and Administration Standard Regimen: One 25mg tablet taken orally, once daily. Administration: Must be taken with food to ensure optimal absorption. Monitoring: Regular monitoring of liver function (ALT levels) and HBV DNA viral load is recommended to assess treatment response. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Myhepdvir—manufactured in world-class Indian facilities—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private clinics and specialized hepatology centers in London and across the UK. United States: Providing affordable access for specialized pharmacy requirements and clinical research. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical hubs and specialty clinics. Australia & South Africa: Reliable bulk supply for public health departments and regional medical distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Sofocure V Tablet: The Definitive Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology The landscape of Chronic Hepatitis C (HCV) treatment has reached a historic milestone with the development of “pan-genotypic“ therapies. Sofocure V, a high-potency fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg), represents the gold standard in this evolution. Designed to eliminate the Hepatitis C virus across all six major genotypes, Sofocure V offers a simplified, once-daily oral regimen that achieves unprecedented cure rates. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, WHO-GMP-compliant international distribution of Sofocure V to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Sofocure V? (The Science of Eradication) Sofocure V is a premium generic version of the breakthrough medication Epclusa. It integrates two distinct Direct-Acting Antivirals (DAAs) that work synergistically to stop the virus from replicating and assembling new particles. Unlike traditional therapies of the past, Sofocure V is an all-oral regimen, removing the need for interferon injections and their associated severe side effects. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1–6): A universal treatment for all known HCV genotypes in adults and pediatric patients (3 years and older). Compensated Cirrhosis: Highly effective for patients with early-to-mid-stage liver scarring. Decompensated Cirrhosis: When combined with Ribavirin, it provides a life-saving treatment path for patients with advanced liver disease. HCV/HIV Co-infection: Proven safe for patients managing co-infection, maintaining a stable drug-interaction profile. Detailed Product Information: Sofocure V (400mg/100mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Velpatasvir (100mg) Therapeutic Class: Antiviral (HCV NS5B & NS5A Inhibitor) Manufacturer: Emcure Pharmaceuticals (India) Treatment Duration: Standard 12-Week Course (84 Days) Form: Film-coated tablets (28 Tablets per bottle) Efficacy Rate: >95% Sustained Virologic Response (SVR12) Quality Standard, GMP-Certified Production Mechanism of Action: The Double-Inhibitor Strategy Sofocure V eradicates the virus by attacking two critical phases of its replication cycle: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It acts as a “chain terminator,“ mimicking the building blocks of the virus to halt the replication of viral RNA. Velpatasvir (100mg): An NS5A inhibitor. It blocks the NS5A protein, which the virus essentially requires for both the replication and assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken orally once per day. Administration: Can be taken with or without food. However, it is vital to take the tablet at the same time every day to maintain steady blood levels of the medication. Patient Compliance: Completing the full 12-week course is mandatory to prevent viral resistance and ensure a permanent cure. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complex regulatory and logistical landscapes of the international pharmaceutical trade. We ensure that Sofocure V—manufactured by Emcure Pharmaceuticals—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology networks and “Named Patient“ programs in London and across the UK. United States: Providing affordable access for specialized pharmacy requirements, clinical research, and hospital procurement. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical hubs and specialty clinics. Australia & South Africa: Reliable bulk supply for public health departments, regional medical distributors, and government tenders. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Resof Total Tablet: The Ultimate Pan-Genotypic Breakthrough for Hepatitis C – Global Supply by Ernest Oncology The medical community has witnessed a paradigm shift in the treatment of Chronic Hepatitis C (HCV). Resof Total, a high-potency fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg), represents the gold standard in “pan-genotypic“ therapy. This advanced formulation is designed to simplify the cure for all six major genotypes of the virus, offering a reliable pathway to viral eradication with a single daily tablet. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure, GMP-compliant international distribution of Resof Total to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistics. What is Resof Total? (The Science of Eradication) Resof Total is a generic version of the breakthrough medication Epclusa. It combines two powerful Direct-Acting Antivirals (DAAs) that work synergistically to stop the Hepatitis C virus from replicating. Unlike older treatments that required interferon injections—which often came with severe side effects—Resof Total is an all-oral regimen with a superior safety profile. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1–6): The first-line choice for adults and pediatric patients (3 years and older) across all genotypes. Patients with Cirrhosis: Highly effective for those with compensated cirrhosis. Advanced Liver Disease: When combined with Ribavirin, it serves as a critical treatment for patients with decompensated cirrhosis. HCV/HIV Co-infection: Proven safe for patients managing both conditions simultaneously. Detailed Product Information: Resof Total (400mg/100mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Velpatasvir (100mg) Drug Class: NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturer: Dr. Reddy’s Laboratories (India) Form: Film-coated tablets (28 Tablets per bottle) Standard Duration, 12 Weeks (84 Days) Efficacy Rate > 97% Sustained Virologic Response (SVR12) Regulatory Status: Manufactured in GMP Certified Facilities Mechanism of Action: The Dual-Inhibitor Advantage Resof Total attacks the virus at two different stages of its life cycle, making it nearly impossible for the virus to develop resistance: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It mimics the building blocks the virus needs to copy its RNA but acts as a “chain terminator,“ stopping the replication process dead in its tracks. Velpatasvir (100mg): An NS5A inhibitor. It blocks the NS5A protein, which the virus requires for both the replication and assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken once daily. Administration: Can be taken with or without food. However, consistency is key—patients should take the dose at the same time every day. Patient Compliance: It is critical to complete the full 12-week course, even if viral loads become undetectable early in the treatment, to ensure a permanent cure. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in navigating the complexities of international pharmaceutical trade. We ensure that Resof Total—manufactured by Dr. Reddy’s Laboratories—reaches our global partners through verified, legal, and temperature-controlled channels. United Kingdom & London: Supporting private hepatology networks and named-patient programs in London and across the UK. United States: Providing affordable access for clinical research, specialized pharmacies, and patient advocacy groups. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical diagnostic and treatment hubs. Australia & South Africa: Reliable bulk supply for public health departments, regional distributors, and NGOs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Myhep All Tablet: The Definitive Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology The introduction of pan-genotypic Direct-Acting Antivirals (DAAs) has redefined the clinical approach to Chronic Hepatitis C (HCV). Myhep All, a potent fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg), is at the forefront of this medical revolution. It is specifically engineered to treat all six major genotypes of the Hepatitis C Virus with a simplified, once-daily oral regimen, boasting cure rates that have effectively made HCV a manageable and eradicable disease. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a leading Exporter, Bulk Supplier, and Distributor from India. We ensure the secure, verified international distribution of Myhep All to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa through specialized pharmaceutical logistics and cold-chain integrity. What is Myhep All? (The Science of SVR12) Myhep All is a high-quality, generic version of the breakthrough medication Epclusa. By combining two distinct antiviral mechanisms into a single film-coated tablet, Myhep All eliminates the need for painful interferon injections and, for the vast majority of patients, removes the requirement for Ribavirin. Clinical data indicates a Sustained Virologic Response (SVR12)—clinically defined as a cure—in 98% to 100% of patients without cirrhosis or with compensated cirrhosis. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 2, 3, 4, 5, & 6): A universal treatment for all known HCV genotypes in adults and pediatric patients (3 years and older). Patients with Cirrhosis: Highly effective for both compensated and, when used in conjunction with Ribavirin, decompensated cirrhosis (advanced liver scarring). HCV/HIV Co-infection: Safe and effective for patients managing both Hepatitis C and HIV-1, with minimal drug-drug interactions. Detailed Product Information: Myhep All (400mg/100mg) Feature, Technical Specification Active Ingredients: Sofosbuvir (400mg) + Velpatasvir (100mg) Therapeutic Class: NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturers: Mylan (Viatris) / Natco Pharma (India) Form: Film-coated tablets (28 Tablets per bottle) Treatment Duration: Standard 12-week course (84 days) Success Rate: >95% Sustained Virologic Response (SVR) Regulatory Standards, GMP & ISO Certified Manufacturing Mechanism of Action: The Dual-Blockade System Myhep All works by stopping the virus from replicating at two critical stages of its lifecycle: Sofosbuvir (400mg): This is an NS5B RNA-dependent RNA polymerase inhibitor. It acts as a “defective building block“ that terminates the viral RNA chain during replication, effectively stopping the virus from copying its genetic material. Velpatasvir (100mg): This targets the NS5A protein, which is essential for both the replication of the virus and the assembly of new viral particles. By blocking this protein, the virus cannot spread to healthy liver cells. Dosage and Administration Standard Regimen: One tablet taken once daily for a duration of 12 weeks. Administration: The tablet can be taken with or without food. It is vital to take the dose at the same time every day to maintain steady blood concentrations and prevent viral rebound. Storage: Store in the original moisture-proof packaging at room temperature (below 30°C) away from direct sunlight. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the global transit of life-saving specialty medicines. We navigate the complex regulatory environments of international pharmaceutical trade to ensure that Myhep All reaches patients and healthcare providers through legal and compliant trade channels. United Kingdom & London: Supporting private hepatology clinics and specialized “Named Patient“ programs throughout the UK. United States: Providing cost-effective access for specialized pharmacy requirements, clinical research, and hospital procurement. Abu Dhabi & UAE: Fast-tracked export to the Middle East’s most advanced medical hubs and specialty pharmacies. Australia & South Africa: Reliable bulk supply for public health initiatives, regional medical distributors, and government tenders. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of specialty antiviral and oncology medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Velakast Tablet: The Advanced Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology In the field of viral hepatology, the development of fixed-dose combinations has transformed Hepatitis C from a chronic, life-threatening condition into a curable one. Velakast, a powerful combination of Sofosbuvir ($400text{mg}$) and Velpatasvir ($100text{mg}$), is a “pan-genotypic“ medication, meaning it is clinically proven to treat all six major genotypes (1–6) of the Hepatitis C Virus (HCV). Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure international distribution of Velakast to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical export channels. What is Velakast? Velakast is a high-quality generic version of the breakthrough drug Epclusa. It is a complete, once-daily oral regimen that eliminates the need for interferon injections. By targeting the virus's ability to replicate, Velakast achieves a cure rate (Sustained Virologic Response) of over 95% across various patient populations. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1-6): The primary treatment for adults and pediatric patients (aged 3 and older). Compensated Cirrhosis: Effective for patients with early-to-mid-stage liver scarring. Decompensated Cirrhosis: When used alongside Ribavirin, Velakast provides a vital treatment path for patients with advanced liver disease. Detailed Product Information: Velakast ($400text{mg}$/$100text{mg}$) Feature,Technical Specification Active Ingredients: Sofosbuvir (400mg) + Velpatasvir (100mg) Drug Class: Direct-Acting Antivirals (DAAs) Manufacturer: Aprazer Healthcare / Natco Pharma (India) Form: Film-coated tablets (28 Tablets per bottle) Treatment Cycle, 12 Weeks (Standard) Quality Standard, GMP-Certified Production Mechanism of Action: The Dual-Inhibitor Advantage Velakast uses two specialized mechanisms to eradicate the virus:Sofosbuvir ($400text{mg}$): An NS5B polymerase inhibitor. It prevents the virus from copying its genetic material (RNA), effectively stopping the virus from reproducing.Velpatasvir ($100text{mg}$): An NS5A inhibitor. It blocks a protein necessary for both the replication and assembly of new virus particles. Dosage and Administration Standard Dose: One tablet taken once daily for a duration of 12 weeks. Administration: The tablet can be taken with or without food. It is essential to maintain a consistent daily schedule to ensure maximum efficacy. Patient Compliance: Completing the full 12-week course is mandatory to prevent viral resistance, even if the patient feels significantly better early in the treatment. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the logistics of life-critical specialty medicines. We ensure that Velakast reaches international healthcare networks through verified legal pathways and strict cold-chain management where necessary. United Kingdom & London: Supporting private hepatology clinics and named-patient programs throughout the UK. United States: Providing affordable access for specialized pharmacy requirements and clinical research. Abu Dhabi & UAE: Fast-track export to the Middle East’s leading medical hubs and diagnostic centers. Australia & South Africa: Reliable bulk supply for public health departments, regional distributors, and NGOs. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in international antiviral and oncology medicine supply. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Velasof Tablet: The Definitive Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology The landscape of Hepatitis C (HCV) treatment has been revolutionized by the introduction of highly effective Direct-Acting Antivirals (DAAs). Velasof, a potent fixed-dose combination of Sofosbuvir (400mg) and Velpatasvir (100mg), stands at the forefront of this medical breakthrough. As a “pan-genotypic“ therapy, it is engineered to treat all six major genotypes of the virus with a single daily tablet. Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier Exporter, Bulk Supplier, and Distributor from India. We ensure the secure, temperature-controlled international distribution of Velasof to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical logistical channels. What is Velasof? Velasof is an authorized generic version of the breakthrough medication Epclusa. It is a complete oral regimen that eliminates the need for interferon injections and, in many cases, avoids the use of Ribavirin. By inhibiting the proteins essential for viral replication, Velasof can achieve a Sustained Virologic Response (SVR12)—clinically defined as a cure—in over 95% to 99% of patients. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1, 2, 3, 4, 5, & 6): The primary choice for adults and pediatric patients (3 years and older) with any HCV genotype. Compensated Cirrhosis: Highly effective for patients with early-stage liver scarring. Decompensated Cirrhosis: When prescribed with Ribavirin, Velasof is a life-saving option for patients with advanced liver disease. Detailed Product Information: Velasof (Sofosbuvir/Velpatasvir) Feature,Technical Specification Active Ingredients,Sofosbuvir (400mg) + Velpatasvir (100mg) Therapeutic Class,Antiviral (HCV NS5B & NS5A Inhibitor) Manufacturer,Hetero Healthcare / Hetero Labs (India) Treatment Duration,12 Weeks (Standard Course) Form,Film-coated tablets (28 Tablets per pack) Quality Standard,WHO-GMP Certified Manufacturing Mechanism of Action: The Dual-Inhibitor Strategy Velasof utilizes two distinct pathways to eradicate the Hepatitis C virus: Sofosbuvir (400mg): An NS5B polymerase inhibitor. It acts as a “chain terminator,“ preventing the virus from copying its genetic material (RNA). Velpatasvir (100mg): An NS5A inhibitor. It blocks a specific protein that the virus requires for both replication and the assembly of new viral particles. Dosage and Administration Standard Regimen: One tablet taken orally, once daily, for 12 consecutive weeks. Administration: Can be taken with or without food. Consistency is critical; missing doses can reduce the effectiveness of the treatment. Storage: Store in a cool, dry place away from direct sunlight at temperatures below 30°C. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology specializes in navigating the complex regulatory environments of international pharmaceutical trade. We ensure that Velasof—manufactured by Hetero Labs under stringent global standards—is accessible to healthcare providers and patients worldwide. United Kingdom & London: Supporting private hepatology clinics and named-patient programs across the UK. United States: Providing cost-effective access for specialized clinical research and patient advocacy groups. Abu Dhabi & UAE: Fast-tracked export for the Middle East’s premier medical hubs and specialty pharmacies. Australia & South Africa: Reliable bulk supply for public health initiatives, regional distributors, and hospital tenders. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in the international supply of oncology and antiviral medicines. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Telura Tablet: The Triple-Combination Breakthrough in HIV-1 Management – Global Supply by Ernest Oncology In the ongoing global effort to manage HIV effectively, Telura stands as a cornerstone of modern Antiretroviral Therapy (ART). As a fixed-dose combination of Tenofovir Disoproxil Fumarate ($300text{mg}$), Lamivudine ($300text{mg}$), and Efavirenz ($600text{mg}$), it simplifies complex treatment schedules into a single, high-efficacy daily pill. What is Telura? Telura is a complete, once-daily regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least $40text{kg}$. It is widely recognized for its clinical reliability and is often used as a first-line treatment in various international health protocols. Primary Indications & Medical Uses HIV-1 Infection Treatment: Used to reduce the viral load to undetectable levels, thereby strengthening the immune system. Long-term Maintenance: Provides a stable, long-term solution for patients who are stable on this specific ART combination. Prevention of Transmission: By suppressing the virus, it significantly reduces the risk of transmitting HIV to others (U=U principle). Detailed Product Information: Telura (TDF/3TC/EFV) Feature,Technical Specification Active Ingredients,Tenofovir Disoproxil Fumarate (300mg) + Lamivudine (300mg) + Efavirenz (600mg) Drug Class,NRTI + NtRTI + NNRTI Combination Manufacturer,Mylan (A Viatris Company) / Hetero Labs (India) Form,Film-coated tablets (30 tablets per bottle) Mechanism,Triple-action viral replication inhibition Telura Tablet: The Triple-Combination Breakthrough in HIV-1 Management – Global Supply by Ernest Oncology In the ongoing global effort to manage HIV effectively, Telura stands as a cornerstone of modern Antiretroviral Therapy (ART). As a fixed-dose combination of Tenofovir Disoproxil Fumarate (300mg), Lamivudine (300mg), and Efavirenz (600mg), it simplifies complex treatment schedules into a single, high-efficacy daily pill. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure international distribution of Telura to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical export channels. What is Telura? Telura is a complete, once-daily regimen for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40kg. It is widely recognized for its clinical reliability and is often used as a first-line treatment in various international health protocols. Primary Indications & Medical Uses HIV-1 Infection Treatment: Used to reduce the viral load to undetectable levels, thereby strengthening the immune system. Long-term Maintenance: Provides a stable, long-term solution for patients who are stable on this specific ART combination. Prevention of Transmission: By suppressing the virus, it significantly reduces the risk of transmitting HIV to others (U=U principle). Detailed Product Information: Telura (TDF/3TC/EFV) Feature Technical Specification Active Ingredients Tenofovir Disoproxil Fumarate (300mg) + Lamivudine (300mg) + Efavirenz (600mg) Drug Class NRTI + NtRTI + NNRTI Combination Manufacturer Mylan (A Viatris Company) / Hetero Labs (India) Form Film-coated tablets (30 tablets per bottle) Mechanism Triple-action viral replication inhibition Mechanism of Action: How it Works Telura attacks the virus using two distinct classes of antiretrovirals: Tenofovir (300mg) & Lamivudine (300mg): These are Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs). They block the reverse transcriptase enzyme, preventing the virus from converting its RNA into DNA. Efavirenz (600mg): A Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) that binds directly to the enzyme to stop it from working. Dosage and Administration Standard Dose: One tablet taken once daily. Administration: It is highly recommended to take Telura on an empty stomach, preferably at bedtime. This helps reduce the severity of potential side effects associated with Efavirenz, such as dizziness or vivid dreams. Consistency: To ensure maximum effectiveness, the tablet should be taken at the same time every day to maintain a steady concentration in the bloodstream. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in international antiviral and oncology medicine supply. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Viropil Tablet: The Advanced Triple-Action HIV Treatment – Global Supply by Ernest Oncology In the modern era of antiretroviral therapy (ART), Viropil represents the pinnacle of “Test and Treat“ efficiency. As a fixed-dose combination of Dolutegravir ($50text{mg}$), Tenofovir Alafenamide ($25text{mg}$), and Lamivudine ($300text{mg}$), it provides a complete, high-barrier regimen in a single daily pill. Ernest Oncology, the specialized pharmaceutical division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure international distribution of Viropil to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical export channels. What is Viropil? Viropil is a generic version of the breakthrough medication Spegra. It is a complete HIV-1 regimen for adults and pediatric patients weighing at least $40text{kg}$. By combining three different classes of antivirals, Viropil suppresses the viral load to undetectable levels, protecting the immune system and preventing transmission. Primary Indications & Medical Uses HIV-1 Infection Treatment: Used as a first-line, single-tablet regimen for newly diagnosed patients and those switching from less effective therapies. High Viral Load Suppression: Highly effective at bringing viral counts down rapidly due to the inclusion of Dolutegravir. Resistance Management: Known for its high genetic barrier to resistance, making it suitable for long-term clinical success. Detailed Product Information: Viropil (DTG/TAF/3TC) Feature,Technical Specification Active Ingredients,Dolutegravir (50mg) + Tenofovir Alafenamide (25mg) + Lamivudine (300mg) Drug Class,INSTI + NRTI + NtRTI Combination Manufacturer,Emcure Pharmaceuticals (India) Form,Film-coated tablets (30 tablets per bottle) Benefits of TAF,Lower bone and kidney toxicity compared to older Tenofovir (TDF) Mechanism of Action: Triple-Layer Protection Viropil works by attacking the virus at different stages of its life cycle: Dolutegravir: An Integrase Strand Transfer Inhibitor (INSTI) that prevents the viral DNA from integrating into the human cell's DNA. Tenofovir Alafenamide & Lamivudine: Both are Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs) that stop the virus from creating new copies of itself. Dosage and Administration Standard Dose: One tablet taken once daily. Administration: Can be taken with or without food. It is crucial to maintain a consistent schedule to prevent viral rebound. Safety Profile: Viropil is generally well-tolerated, with fewer renal and bone-density side effects due to the advanced Tenofovir Alafenamide (TAF) component. Global Reach: Exporting to UK, USA, UAE, Australia, and South Africa Ernest Oncology excels in the logistics of critical antiretrovirals. We ensure that Viropil—manufactured in world-class facilities—reaches international healthcare providers and patients through verified legal pathways. United Kingdom & London: Supporting private health clinics and specialized HIV care networks throughout the UK. United States: Providing affordable access for research and specialized pharmacy requirements. Abu Dhabi & UAE: Rapid export to the Middle East's leading specialty medicine hubs. Australia & South Africa: Reliable bulk supply for public health initiatives and regional distributors. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in international antiviral and oncology medicine supply. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com | www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Velpanat Tablet (Sofosbuvir 400mg & Velpatasvir 100mg): The Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology In the field of hepatology and antiviral research, Velpanat represents a historic milestone. As a fixed-dose combination of Sofosbuvir and Velpatasvir, it is the first “pan-genotypic“ treatment—meaning it is highly effective against all six major genotypes (1-6) of the Hepatitis C Virus (HCV). Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure international distribution of Velpanat to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical export channels. What is Velpanat? Velpanat is a generic version of the breakthrough medication Epclusa. It combines two powerful direct-acting antivirals (DAAs) into a single, once-daily tablet. By targeting the virus directly, Velpanat can achieve cure rates exceeding 95% in most patient populations. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1-6): Used to treat adults and children (aged 3 years and older) with chronic HCV infection. Patients with Cirrhosis: Effective for patients without cirrhosis or those with compensated cirrhosis. Decompensated Cirrhosis: When used in combination with Ribavirin, it is a primary choice for patients with advanced (decompensated) liver scarring. Feature,Technical Specification Active Ingredients,Sofosbuvir (400mg) + Velpatasvir (100mg) Drug Class,Direct-Acting Antivirals (DAAs) Mechanism,NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturer,Natco Pharma Ltd. (India) Form,Film-coated tablets (28 tablets per bottle) Success Rate,Over 95% Sustained Virologic Response (SVR) Velpanat Tablet (Sofosbuvir 400mg & Velpatasvir 100mg): The Pan-Genotypic Cure for Hepatitis C – Global Supply by Ernest Oncology In the field of hepatology and antiviral research, Velpanat represents a historic milestone. As a fixed-dose combination of Sofosbuvir and Velpatasvir, it is the first “pan-genotypic“ treatment—meaning it is highly effective against all six major genotypes (1-6) of the Hepatitis C Virus (HCV). Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a trusted Exporter, Bulk Supplier, and Distributor from India. We facilitate the secure international distribution of Velpanat to the UK (London), USA, Abu Dhabi (UAE), Australia, and South Africa via specialized pharmaceutical export channels. What is Velpanat? Velpanat is a generic version of the breakthrough medication Epclusa. It combines two powerful direct-acting antivirals (DAAs) into a single, once-daily tablet. By targeting the virus directly, Velpanat can achieve cure rates exceeding 95% in most patient populations. Primary Indications & Medical Uses Chronic Hepatitis C (Genotypes 1-6): Used to treat adults and children (aged 3 years and older) with chronic HCV infection. Patients with Cirrhosis: Effective for patients without cirrhosis or those with compensated cirrhosis. Decompensated Cirrhosis: When used in combination with Ribavirin, it is a primary choice for patients with advanced (decompensated) liver scarring. Detailed Product Information: Velpanat 400mg/100mg Feature Technical Specification Active Ingredients Sofosbuvir (400mg) + Velpatasvir (100mg) Drug Class Direct-Acting Antivirals (DAAs) Mechanism NS5B Polymerase Inhibitor + NS5A Inhibitor Manufacturer Natco Pharma Ltd. (India) Form Film-coated tablets (28 tablets per bottle) Success Rate Over 95% Sustained Virologic Response (SVR) Mechanism of Action: How It Works Velpanat uses a “double-lock“ mechanism to eradicate the virus: Sofosbuvir (400mg): Acts as a “chain terminator.“ It mimics the virus's genetic building blocks, tricking the NS5B polymerase enzyme into stopping the replication of viral RNA. Velpatasvir (100mg): Targets the NS5A protein, which is essential for both the replication and the assembly of new virus particles. Dosage and Administration Standard Dose: One tablet taken once daily for a duration of 12 weeks. Administration: Can be taken with or without food. It is vital to take the tablet at the same time every day to maintain consistent medicine levels in the blood. Full Course: Patients must complete the entire 12-week course even if they begin to feel better within the first few days. 📞 Contact Ernest Oncology — Pharmaceutical Exporter from India (Group of Ernest Pharmaceutical Pvt. Ltd.) Partner with a verified leader in international antiviral and oncology medicine supply. 🌐 Websites: www.oncologymedicinesupplier.com | www.ernestpharmaceuticals.com | www.ernestimpex.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Exporter | Bulk Supplier | Distributor 📲 WhatsApp: +91 93599 02383 🔗 Instant Chat: https://wa.me/919359902383

Sutinat 25mg Capsule (Sunitinib): Targeted Multi-Kinase Inhibition for Advanced Malignancies Sutinat 25mg Capsule is a high-potency oral antineoplastic medication featuring the active pharmaceutical ingredient Sunitinib. Classified as a multi-targeted receptor tyrosine kinase (RTK) inhibitor, Sutinat is a cornerstone in modern precision medicine. Manufactured by Natco Pharma Ltd., a global leader in high-quality oncology generics, it is engineered to disrupt the life cycle of cancer cells by blocking specific signaling pathways that promote tumor growth, cellular division, and vascularization. The 25 mg strength is a critical dosage for precise titration, ensuring that patients receive the optimal therapeutic benefit while maintaining systemic tolerability. Therapeutic Indications and Clinical Usage Sutinat 25mg is utilized globally in advanced oncology protocols for several aggressive malignancies: Advanced Renal Cell Carcinoma (RCC): Used as a primary first-line treatment for metastatic kidney cancer to prolong progression-free survival. Gastrointestinal Stromal Tumor (GIST): Indicated for patients whose disease has progressed or who are intolerant to previous treatments like imatinib mesylate. Pancreatic Neuroendocrine Tumors (pNET): Prescribed for progressive, well-differentiated pNET in patients with unresectable locally advanced or metastatic disease. Adjuvant Treatment for RCC: In specific high-risk scenarios, it is utilized to reduce the risk of cancer recurrence following a nephrectomy (surgical removal of the kidney). Mechanism of Action: How Sutinat 25mg Works Sutinat employs a dual-action strategy to combat tumor progression by targeting various receptors involved in cancer development: Anti-Angiogenesis: It inhibits receptors for Vascular Endothelial Growth Factor (VEGFR) and Platelet-Derived Growth Factor (PDGFR). This effectively “starves“ the tumor by preventing the formation of new blood vessels it needs to grow. Proliferation Blockade: It targets various other receptor tyrosine kinases (such as KIT, FLT3, and RET) that drive the rapid, uncontrolled division of malignant cells. Metastasis Inhibition: By disrupting these vital signaling pathways, Sutinat helps limit the cancer's ability to invade surrounding tissues or migrate to distant organs. Dosage and Administration Guidelines Administration: Sutinat 25 mg is taken orally. Capsules must be swallowed whole with water; do not crush or chew. Standard Regimen (RCC/GIST): Typically involves a cycle of 4 weeks on treatment followed by 2 weeks off (the 4/2 schedule). Continuous Regimen (pNET): Often prescribed as a continuous daily dose (usually 37.5mg, often achieved using combination strengths) without a rest period. Flexibility: The 25mg strength is essential for dose modifications required to manage side effects while maintaining therapeutic efficacy. Consistency: It can be taken with or without food, but taking it at a consistent time each day is recommended. Safety Profile and Professional Monitoring Treatment with Sutinat 25 mg requires consistent medical oversight to manage potential side effects: Cardiovascular Monitoring: Regular blood pressure checks are essential, as Sunitinib frequently causes hypertension. Hematological Vigilance: Periodic Complete Blood Counts (CBC) are necessary to monitor for neutropenia or thrombocytopenia. Thyroid Function: Patients should have their thyroid levels (TSH) checked periodically, as hypothyroidism is a common side effect of TKI therapy. Skin and Hair Changes: Patients may experience skin yellowing (discoloration), hair depigmentation, or hand-foot syndrome. Liver & Heart Health: Periodic monitoring of liver enzymes and heart function (LVEF) is standard clinical practice. Why Choose Ernest Oncology? Ernest Oncology, a Group of Ernest Pharmaceutical Pvt. Ltd., is a trusted global pharmaceutical exporter from India supplying oncology medicines worldwide. ✔ GMP quality medicines ✔ Global pharmaceutical exporter ✔ Bulk supply for hospitals and distributors ✔ Competitive international pricing ✔ Secure export packaging ✔ Worldwide shipping and export documentation support We export medicines to: USA • UK • UAE • Australia • Singapore • South Africa • Europe • Middle East • Africa • Asia Contact Ernest Oncology—Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383